Official source Data mirrored from Centers for Medicare & Medicaid Services Open Payments · General Payments · CMS publication 2026-06-30 View official record

Covered recipient · General Payments record

HING SHEUNG EUGENE FUNG

Allopathic & Osteopathic Physicians Internal Medicine Rheumatology

NPI
1073624292
CMS profile
320477
Location
WACO, TX

A name match is not confirmation of identity. CMS publishes records for different people under similar names; the NPI, specialty, and location shown on this page are the CMS-published fields that distinguish them.

Saved items

Saved only in this browser. No account or alerts.

Filter and download payment records

General Payments · PY2021 · Entire year

$29,245.77

213 records · 0 disputed

Summary and payment records

  • CMS publication 2026-06-30
Read the payment records

“Financial relationships do not necessarily indicate an improper relationship; the data is open to interpretation.”

— Centers for Medicare & Medicaid Services, Open Payments

A reported payment reflects a financial relationship a company disclosed. It does not indicate wrongdoing or a conflict of interest, and it says nothing about the quality of a provider's care.

These records are submitted to CMS and attested to by the reporting companies. CMS publishes them as reported; this site mirrors them without independent verification.

A payment attributed to a provider may have been made to a third party — a hospital, practice, or research institution — rather than paid to the provider personally.

How these totals are calculated
  • This total is the sum of the individual General Payments record amounts CMS published for the labeled program year(s); each record amount is used unmodified. The total itself is computed by this site. Nothing is estimated, weighted, or combined across categories.
  • General Payments only. Research and Ownership/Investment are separate datasets and are never summed with these figures; amounts are kept separate per program year.
  • Methodology & Data — sourcing, labeling, and limitations.

Provider summaries generated . CMS updates this data on an annual cycle, and corrections or successful disputes made at CMS may not yet appear here. The official CMS record is authoritative for the current state. View the official CMS record ↗

By nature of payment

PY2021 · entire year · sorted by reported total

By paying entity

PY2021 · entire year · sorted by reported total

Page 2 of 5; records 51–100 of 213 matching records. This page contains 50 records (maximum 50), not the full filtered export. Use the CSV download for all matching records.

IndustryPayments · General Payments

HING SHEUNG EUGENE FUNG

NPI 1073624292 · CMS profile ID 320477

Allopathic & Osteopathic Physicians / Internal Medicine / Rheumatology

WACO, TX

A name match is not confirmation of identity. CMS publishes records for different people under similar names; the NPI, specialty, and location shown on this page are the CMS-published fields that distinguish them.

A payment attributed to a provider may have been made to a third party — a hospital, practice, or research institution — rather than paid to the provider personally.

General Payments, PY2021; Recipient scope: Physicians and non-physician practitioners; Reporting company: All reporting companies; Nature of payment: All payment types

Data edition: cms-20260630-workflow-20261105-v2; CMS publication: 2026-06-30; records imported: 2026-11-05T09:06:52.159882+00:00

Page 2 of 5; records 51–100 of 213 matching records. This page contains 50 records (maximum 50), not the full filtered export.

Filtered page: https://industrypayments.org/provider/npi-1073624292?year=2021&recipient=provider&page=2#records-h

CMS source: https://openpaymentsdata.cms.gov/dataset/0380bbeb-aea1-58b6-b708-829f92a48202

Cite these filtered records

The citation includes this program year, filters, data edition, and page of results.

Plain
HING SHEUNG EUGENE FUNG, NPI 1073624292, CMS profile ID 320477. General Payments, PY2021; Recipient scope: Physicians and non-physician practitioners; Reporting company: All reporting companies; Nature of payment: All payment types. Data edition: cms-20260630-workflow-20261105-v2; CMS publication: 2026-06-30; records imported: 2026-11-05T09:06:52.159882+00:00. Page 2 of 5; records 51–100 of 213 matching records. This page contains 50 records (maximum 50), not the full filtered export. IndustryPayments. https://industrypayments.org/provider/npi-1073624292?year=2021&recipient=provider&page=2#records-h. Source: https://openpaymentsdata.cms.gov/dataset/0380bbeb-aea1-58b6-b708-829f92a48202.
APA 7
IndustryPayments. (2026). HING SHEUNG EUGENE FUNG, NPI 1073624292, CMS profile ID 320477. General Payments, PY2021; Recipient scope: Physicians and non-physician practitioners; Reporting company: All reporting companies; Nature of payment: All payment types. Data edition: cms-20260630-workflow-20261105-v2; CMS publication: 2026-06-30; records imported: 2026-11-05T09:06:52.159882+00:00. Page 2 of 5; records 51–100 of 213 matching records. This page contains 50 records (maximum 50), not the full filtered export. [Filtered data set page]. https://industrypayments.org/provider/npi-1073624292?year=2021&recipient=provider&page=2#records-h. Source: https://openpaymentsdata.cms.gov/dataset/0380bbeb-aea1-58b6-b708-829f92a48202.
Bluebook
HING SHEUNG EUGENE FUNG, NPI 1073624292, CMS profile ID 320477, IndustryPayments, General Payments, PY2021; Recipient scope: Physicians and non-physician practitioners; Reporting company: All reporting companies; Nature of payment: All payment types (Data edition: cms-20260630-workflow-20261105-v2; CMS publication: 2026-06-30; records imported: 2026-11-05T09:06:52.159882+00:00). Page 2 of 5; records 51–100 of 213 matching records. This page contains 50 records (maximum 50), not the full filtered export. Source: https://openpaymentsdata.cms.gov/dataset/0380bbeb-aea1-58b6-b708-829f92a48202. https://industrypayments.org/provider/npi-1073624292?year=2021&recipient=provider&page=2#records-h.

Centers for Medicare & Medicaid Services, Open Payments

Citation formats are provided for reference; check the requirements of your publication.

Payment records · PY2021

Ordering applied by this site (date, newest first, then paying entity) · record values are shown as CMS published them

General Payments · PY2021 · Physicians and non-physician practitioners · CMS publication 2026-06-30

213 matching records · $29,245.77 reported total · 0 disputed

Nature of payment: All payment types

Records imported here (UTC).

Link to these filtered records · CMS source dataset ↗

Download all 213 matching records (CSV)

CSV includes CMS record IDs, source and publication dates, the data edition, and a link to these filters. Formula-like text cells are prefixed with an apostrophe for spreadsheet safety.

Showing records 51–100 of 213.

Paying entityAmountDate Nature of paymentDispute statusPublication flagsPublished Record IDSource
Amgen Inc. $13.0910/11/2021 Food and Beverage No dispute reported Delay: No
Change: UNCHANGED
06/30/2026 825355141 CMS
AbbVie Inc. $15.5810/07/2021 Food and Beverage No dispute reported Delay: No
Change: UNCHANGED
06/30/2026 794526693 CMS
Biogen, Inc. $14.4010/07/2021 Food and Beverage No dispute reported Delay: No
Change: UNCHANGED
06/30/2026 827766075 CMS
UCB, Inc. $19.6909/27/2021 Food and Beverage No dispute reported Delay: No
Change: UNCHANGED
06/30/2026 807325019 CMS
E.R. Squibb & Sons, L.L.C. $95.1209/23/2021 Food and Beverage No dispute reported Delay: No
Change: UNCHANGED
06/30/2026 783496659 CMS
Horizon Therapeutics plc $16.8409/23/2021 Food and Beverage No dispute reported Delay: No
Change: UNCHANGED
06/30/2026 797127103 CMS
Amgen Inc. $74.6309/22/2021 Food and Beverage No dispute reported Delay: No
Change: UNCHANGED
06/30/2026 825355173 CMS
E.R. Squibb & Sons, L.L.C. $16.8409/22/2021 Food and Beverage No dispute reported Delay: No
Change: UNCHANGED
06/30/2026 783496661 CMS
Aurinia Pharma U.S., Inc. $29.3309/21/2021 Food and Beverage No dispute reported Delay: No
Change: UNCHANGED
06/30/2026 841397785 CMS
UCB, Inc. $23.5409/20/2021 Food and Beverage No dispute reported Delay: No
Change: UNCHANGED
06/30/2026 807411585 CMS
AbbVie Inc. $14.9409/15/2021 Food and Beverage No dispute reported Delay: No
Change: UNCHANGED
06/30/2026 794526689 CMS
Horizon Therapeutics plc $92.3309/14/2021 Food and Beverage No dispute reported Delay: No
Change: UNCHANGED
06/30/2026 797127089 CMS
Horizon Therapeutics plc $3,264.0009/14/2021 Honoraria No dispute reported Delay: No
Change: UNCHANGED
06/30/2026 797127095 CMS
Horizon Therapeutics plc $1,045.4209/14/2021 Travel and Lodging No dispute reported Delay: No
Change: UNCHANGED
06/30/2026 797127099 CMS
PFIZER INC. $21.0709/14/2021 Food and Beverage No dispute reported Delay: No
Change: UNCHANGED
06/30/2026 833252297 CMS
Boehringer Ingelheim Pharmaceuticals, Inc. $17.3009/09/2021 Food and Beverage No dispute reported Delay: No
Change: UNCHANGED
06/30/2026 763326370 CMS
Janssen Biotech, Inc. $14.3609/08/2021 Food and Beverage No dispute reported Delay: No
Change: UNCHANGED
06/30/2026 788999333 CMS
AbbVie Inc. $12.3709/07/2021 Food and Beverage No dispute reported Delay: No
Change: UNCHANGED
06/30/2026 794526685 CMS
Lilly USA, LLC $1,150.0009/03/2021 Compensation for services other than consulting, including serving as faculty or as a speaker at a venue other than a continuing education program No dispute reported Delay: No
Change: UNCHANGED
06/30/2026 819194079 CMS
Amgen Inc. $15.9609/02/2021 Food and Beverage No dispute reported Delay: No
Change: UNCHANGED
06/30/2026 825355129 CMS
Amgen Inc. $21.7309/01/2021 Food and Beverage No dispute reported Delay: No
Change: UNCHANGED
06/30/2026 825355169 CMS
AstraZeneca Pharmaceuticals LP $10.5008/31/2021 Food and Beverage No dispute reported Delay: No
Change: UNCHANGED
06/30/2026 829582443 CMS
E.R. Squibb & Sons, L.L.C. $13.8808/31/2021 Food and Beverage No dispute reported Delay: No
Change: UNCHANGED
06/30/2026 783496647 CMS
Lilly USA, LLC $71.2008/31/2021 Food and Beverage No dispute reported Delay: No
Change: UNCHANGED
06/30/2026 819174725 CMS
Novartis Pharmaceuticals Corporation $24.4208/30/2021 Food and Beverage No dispute reported Delay: No
Change: UNCHANGED
06/30/2026 812684041 CMS
AbbVie Inc. $15.2108/26/2021 Food and Beverage No dispute reported Delay: No
Change: UNCHANGED
06/30/2026 794526681 CMS
Horizon Therapeutics plc $1,530.0008/26/2021 Honoraria No dispute reported Delay: No
Change: UNCHANGED
06/30/2026 797127081 CMS
Horizon Therapeutics plc $73.0008/26/2021 Consulting Fee No dispute reported Delay: No
Change: UNCHANGED
06/30/2026 797127085 CMS
UCB, Inc. $17.3908/25/2021 Food and Beverage No dispute reported Delay: No
Change: UNCHANGED
06/30/2026 807414697 CMS
Janssen Biotech, Inc. $22.3108/24/2021 Food and Beverage No dispute reported Delay: No
Change: UNCHANGED
06/30/2026 788999329 CMS
UCB, Inc. $15.8108/23/2021 Food and Beverage No dispute reported Delay: No
Change: UNCHANGED
06/30/2026 807314863 CMS
Aurinia Pharma U.S., Inc. $110.9308/19/2021 Food and Beverage No dispute reported Delay: No
Change: UNCHANGED
06/30/2026 841397781 CMS
E.R. Squibb & Sons, L.L.C. $3.2308/19/2021 Food and Beverage No dispute reported Delay: No
Change: UNCHANGED
06/30/2026 783496637 CMS
E.R. Squibb & Sons, L.L.C. $7.7708/19/2021 Food and Beverage No dispute reported Delay: No
Change: UNCHANGED
06/30/2026 783496639 CMS
E.R. Squibb & Sons, L.L.C. $0.8008/19/2021 Food and Beverage No dispute reported Delay: No
Change: UNCHANGED
06/30/2026 783496641 CMS
Horizon Therapeutics plc $20.7008/19/2021 Food and Beverage No dispute reported Delay: No
Change: UNCHANGED
06/30/2026 797127077 CMS
Amgen Inc. $15.3808/18/2021 Food and Beverage No dispute reported Delay: No
Change: UNCHANGED
06/30/2026 825355165 CMS
AstraZeneca Pharmaceuticals LP $600.0008/18/2021 Compensation for services other than consulting, including serving as faculty or as a speaker at a venue other than a continuing education program No dispute reported Delay: No
Change: UNCHANGED
06/30/2026 829471517 CMS
Aurinia Pharma U.S., Inc. $19.6908/18/2021 Education No dispute reported Delay: No
Change: UNCHANGED
06/30/2026 841397777 CMS
Amgen Inc. $25.5408/17/2021 Food and Beverage No dispute reported Delay: No
Change: UNCHANGED
06/30/2026 825355213 CMS
AstraZeneca Pharmaceuticals LP $92.3408/17/2021 Food and Beverage No dispute reported Delay: No
Change: UNCHANGED
06/30/2026 829401333 CMS
Octapharma USA, Inc. $64.4208/11/2021 Food and Beverage No dispute reported Delay: No
Change: UNCHANGED
06/30/2026 812974071 CMS
ARBOR PHARMACEUTICALS, INC. $11.5108/09/2021 Food and Beverage No dispute reported Delay: No
Change: UNCHANGED
06/30/2026 830975391 CMS
AbbVie Inc. $22.5508/04/2021 Food and Beverage No dispute reported Delay: No
Change: UNCHANGED
06/30/2026 794526677 CMS
Lilly USA, LLC $16.1908/03/2021 Food and Beverage No dispute reported Delay: No
Change: UNCHANGED
06/30/2026 819112797 CMS
Aurinia Pharma U.S., Inc. $18.6608/02/2021 Food and Beverage No dispute reported Delay: No
Change: UNCHANGED
06/30/2026 841397773 CMS
E.R. Squibb & Sons, L.L.C. $14.4708/02/2021 Food and Beverage No dispute reported Delay: No
Change: UNCHANGED
06/30/2026 783496645 CMS
Novartis Pharmaceuticals Corporation $15.5807/30/2021 Food and Beverage No dispute reported Delay: No
Change: UNCHANGED
06/30/2026 812684031 CMS
Janssen Biotech, Inc. $17.7807/29/2021 Food and Beverage No dispute reported Delay: No
Change: UNCHANGED
06/30/2026 788999345 CMS
AbbVie Inc. $11.0007/28/2021 Food and Beverage No dispute reported Delay: No
Change: UNCHANGED
06/30/2026 794526673 CMS

By program year

All program years on this page · sorted by year

Program yearAmountRecords
PY2019 $60,107.82 270
PY2020 $34,759.29 212
PY2021 $29,245.77 213
PY2022 $58,443.55 261
PY2023 $28,537.51 232
PY2024 $33,260.88 238
PY2025 $21,357.66 46

Source & provenance

Dataset
CMS Open Payments — General Payments
Publisher of source data
Centers for Medicare & Medicaid Services
CMS publication date
2026-06-30
Program years on this page
2019, 2020, 2021, 2022, 2023, 2024, 2025
Source files and profile matching
Generated from
OP_DTL_GNRL_PGYR2025_P06302026_06032026.csv

One page per canonical provider; split Profile_IDs are merged via Associated_Covered_Recipient_Profile_ID_1/_2 from the Covered Recipient Profile Supplement.

Corrections to the substance of a record route to CMS through its review-and-dispute process; errors in how this site mirrors or displays a record route to us. Both paths are described in Methodology & Data.

Research Payments

One row per program year and role, newest year first · amounts for the two roles are never added together

Program yearRoleAmountRecords
PY2025 Recipient $10,000.00 3
PY2025 Principal investigator $99,608.40 121
PY2024 Principal investigator $101,330.70 71
PY2023 Principal investigator $142,611.83 66
PY2022 Principal investigator $187,578.09 85
PY2021 Principal investigator $236,627.32 62
PY2020 Recipient $6,408.70 3
PY2020 Principal investigator $345,659.60 69
PY2019 Principal investigator $206,868.06 70

Research Payments are a separate CMS dataset, shown here separately and never added to General Payments. A research payment is often made to an institution, with this provider named as a principal investigator; each record states which role applies.

“If you are a physician who served as a principal investigator on a research study, you may see the payments associated with that research study listed under your name. This does not necessarily mean the payments are attributed to you. The dollar amount of the record corresponds to the total payment; the amounts are not attributed to each individual on the record.”

— Centers for Medicare & Medicaid Services, Open Payments Frequently Asked Questions, FAQ #12224

Research Payments records · PY2025

Ordering applied by this site (date, newest first, then paying entity) · record values are shown as CMS published them

121 records in PY2025

Research Payments records (CSV)

RolePaying entityAmount DateRecipientStudy Dispute statusPublishedRecord ID
Principal investigator 1 Janssen Research & Development, LLC $230.00 12/19/2025 Non-covered Recipient Entity
Hing Sheung Eugene Fung MD Pa
A Study of Guselkumab in Participants With Active Psoriatic Arthritis (APEX) No dispute reported 06/30/2026 1175291408
Principal investigator 1 Janssen Research & Development, LLC $67.00 12/19/2025 Non-covered Recipient Entity
Hing Sheung Eugene Fung MD Pa
A Study of Guselkumab in Participants With Active Psoriatic Arthritis (APEX) No dispute reported 06/30/2026 1175291537
Principal investigator 1 Janssen Research & Development, LLC $1,764.00 11/27/2025 Non-covered Recipient Entity
Hing Sheung Eugene Fung MD Pa
A Study of Guselkumab in Participants With Active Psoriatic Arthritis (APEX) No dispute reported 06/30/2026 1175290978
Principal investigator 1 Janssen Research & Development, LLC $67.00 11/27/2025 Non-covered Recipient Entity
Hing Sheung Eugene Fung MD Pa
A Study of Guselkumab in Participants With Active Psoriatic Arthritis (APEX) No dispute reported 06/30/2026 1175291016
Principal investigator 1 Janssen Research & Development, LLC $67.00 11/27/2025 Non-covered Recipient Entity
Hing Sheung Eugene Fung MD Pa
A Study of Guselkumab in Participants With Active Psoriatic Arthritis (APEX) No dispute reported 06/30/2026 1175291126
Principal investigator 1 Janssen Research & Development, LLC $1,383.00 11/27/2025 Non-covered Recipient Entity
Hing Sheung Eugene Fung MD Pa
A Study of Guselkumab in Participants With Active Psoriatic Arthritis (APEX) No dispute reported 06/30/2026 1175291166
Principal investigator 1 Janssen Research & Development, LLC $67.00 11/27/2025 Non-covered Recipient Entity
Hing Sheung Eugene Fung MD Pa
A Study of Guselkumab in Participants With Active Psoriatic Arthritis (APEX) No dispute reported 06/30/2026 1175291173
Principal investigator 1 Janssen Research & Development, LLC $67.00 11/27/2025 Non-covered Recipient Entity
Hing Sheung Eugene Fung MD Pa
A Study of Guselkumab in Participants With Active Psoriatic Arthritis (APEX) No dispute reported 06/30/2026 1175291228
Principal investigator 1 Janssen Research & Development, LLC $1,256.00 11/27/2025 Non-covered Recipient Entity
Hing Sheung Eugene Fung MD Pa
A Study of Guselkumab in Participants With Active Psoriatic Arthritis (APEX) No dispute reported 06/30/2026 1175291402
Principal investigator 1 Janssen Research & Development, LLC $67.00 11/27/2025 Non-covered Recipient Entity
Hing Sheung Eugene Fung MD Pa
A Study of Guselkumab in Participants With Active Psoriatic Arthritis (APEX) No dispute reported 06/30/2026 1175291419
Principal investigator 1 Janssen Research & Development, LLC $230.00 11/27/2025 Non-covered Recipient Entity
Hing Sheung Eugene Fung MD Pa
A Study of Guselkumab in Participants With Active Psoriatic Arthritis (APEX) No dispute reported 06/30/2026 1175291571
Principal investigator 1 Janssen Research & Development, LLC $1,764.00 11/27/2025 Non-covered Recipient Entity
Hing Sheung Eugene Fung MD Pa
A Study of Guselkumab in Participants With Active Psoriatic Arthritis (APEX) No dispute reported 06/30/2026 1175291640
Principal investigator 1 GlaxoSmithKline, LLC. $3,557.00 09/03/2025 Non-covered Recipient Entity
HING-SHEUNG EUGENE FUNG MD PA
A PHASE 4, MULTICENTER, PROSPECTIVE, OPEN-LABEL STUDY DESCRIBING THE E No dispute reported 06/30/2026 1192167766
Principal investigator 1 GlaxoSmithKline, LLC. $1,500.00 09/03/2025 Non-covered Recipient Entity
HING-SHEUNG EUGENE FUNG MD PA
A PHASE 4, MULTICENTER, PROSPECTIVE, OPEN-LABEL STUDY DESCRIBING THE E No dispute reported 06/30/2026 1192167770
Principal investigator 1 Janssen Research & Development, LLC $67.00 08/28/2025 Non-covered Recipient Entity
Hing Sheung Eugene Fung MD Pa
A Study of Guselkumab in Participants With Active Psoriatic Arthritis (APEX) No dispute reported 06/30/2026 1175291151
Principal investigator 1 Janssen Research & Development, LLC $230.00 08/28/2025 Non-covered Recipient Entity
Hing Sheung Eugene Fung MD Pa
A Study of Guselkumab in Participants With Active Psoriatic Arthritis (APEX) No dispute reported 06/30/2026 1175291197
Principal investigator 1 Janssen Research & Development, LLC $1,764.00 08/28/2025 Non-covered Recipient Entity
Hing Sheung Eugene Fung MD Pa
A Study of Guselkumab in Participants With Active Psoriatic Arthritis (APEX) No dispute reported 06/30/2026 1175291242
Principal investigator 1 Janssen Research & Development, LLC $1,256.00 08/28/2025 Non-covered Recipient Entity
Hing Sheung Eugene Fung MD Pa
A Study of Guselkumab in Participants With Active Psoriatic Arthritis (APEX) No dispute reported 06/30/2026 1175291320
Principal investigator 1 Janssen Research & Development, LLC $67.00 08/28/2025 Non-covered Recipient Entity
Hing Sheung Eugene Fung MD Pa
A Study of Guselkumab in Participants With Active Psoriatic Arthritis (APEX) No dispute reported 06/30/2026 1175291379
Principal investigator 1 Janssen Research & Development, LLC $1,383.00 08/28/2025 Non-covered Recipient Entity
Hing Sheung Eugene Fung MD Pa
A Study of Guselkumab in Participants With Active Psoriatic Arthritis (APEX) No dispute reported 06/30/2026 1175291387
Principal investigator 1 Janssen Research & Development, LLC $67.00 08/28/2025 Non-covered Recipient Entity
Hing Sheung Eugene Fung MD Pa
A Study of Guselkumab in Participants With Active Psoriatic Arthritis (APEX) No dispute reported 06/30/2026 1175291492
Principal investigator 1 Janssen Research & Development, LLC $67.00 08/28/2025 Non-covered Recipient Entity
Hing Sheung Eugene Fung MD Pa
A Study of Guselkumab in Participants With Active Psoriatic Arthritis (APEX) No dispute reported 06/30/2026 1175291627
Principal investigator 1 ARGENX US, INC. $106.00 07/01/2025 Non-covered Recipient Entity
Velocity Clinical Research
Quincy Model A Phase 3 Randomized Double Blinded Placebo Controlled Multicenter Trial to Evaluate the Efficacy Safety and Tolerability of Efgartigimod PH20 Subcutaneous Administered by Prefilled Syringe in Adult Patients with Primary Sjogrens Syndrome No dispute reported 06/30/2026 1237161302
Principal investigator 1 ARGENX US, INC. $75.20 07/01/2025 Non-covered Recipient Entity
Velocity Clinical Research
Quincy Model A Phase 3 Randomized Double Blinded Placebo Controlled Multicenter Trial to Evaluate the Efficacy Safety and Tolerability of Efgartigimod PH20 Subcutaneous Administered by Prefilled Syringe in Adult Patients with Primary Sjogrens Syndrome No dispute reported 06/30/2026 1237161306
Principal investigator 1 ARGENX US, INC. $26.50 07/01/2025 Non-covered Recipient Entity
Velocity Clinical Research
Quincy Model A Phase 3 Randomized Double Blinded Placebo Controlled Multicenter Trial to Evaluate the Efficacy Safety and Tolerability of Efgartigimod PH20 Subcutaneous Administered by Prefilled Syringe in Adult Patients with Primary Sjogrens Syndrome No dispute reported 06/30/2026 1237161310
Principal investigator 1 ARGENX US, INC. $3.85 07/01/2025 Non-covered Recipient Entity
Velocity Clinical Research
Quincy Model A Phase 3 Randomized Double Blinded Placebo Controlled Multicenter Trial to Evaluate the Efficacy Safety and Tolerability of Efgartigimod PH20 Subcutaneous Administered by Prefilled Syringe in Adult Patients with Primary Sjogrens Syndrome No dispute reported 06/30/2026 1237161314
Principal investigator 1 ARGENX US, INC. $51.75 07/01/2025 Non-covered Recipient Entity
Velocity Clinical Research
Quincy Model A Phase 3 Randomized Double Blinded Placebo Controlled Multicenter Trial to Evaluate the Efficacy Safety and Tolerability of Efgartigimod PH20 Subcutaneous Administered by Prefilled Syringe in Adult Patients with Primary Sjogrens Syndrome No dispute reported 06/30/2026 1237161318
Principal investigator 1 ARGENX US, INC. $382.00 07/01/2025 Non-covered Recipient Entity
Velocity Clinical Research
Quincy Model A Phase 3 Randomized Double Blinded Placebo Controlled Multicenter Trial to Evaluate the Efficacy Safety and Tolerability of Efgartigimod PH20 Subcutaneous Administered by Prefilled Syringe in Adult Patients with Primary Sjogrens Syndrome No dispute reported 06/30/2026 1237161322
Principal investigator 1 ARGENX US, INC. $286.50 07/01/2025 Non-covered Recipient Entity
Velocity Clinical Research
Quincy Model A Phase 3 Randomized Double Blinded Placebo Controlled Multicenter Trial to Evaluate the Efficacy Safety and Tolerability of Efgartigimod PH20 Subcutaneous Administered by Prefilled Syringe in Adult Patients with Primary Sjogrens Syndrome No dispute reported 06/30/2026 1237161326
Principal investigator 1 ARGENX US, INC. $2.80 07/01/2025 Non-covered Recipient Entity
Velocity Clinical Research
Quincy Model A Phase 3 Randomized Double Blinded Placebo Controlled Multicenter Trial to Evaluate the Efficacy Safety and Tolerability of Efgartigimod PH20 Subcutaneous Administered by Prefilled Syringe in Adult Patients with Primary Sjogrens Syndrome No dispute reported 06/30/2026 1237161328
Principal investigator 1 ARGENX US, INC. $35.80 07/01/2025 Non-covered Recipient Entity
Velocity Clinical Research
Quincy Model A Phase 3 Randomized Double Blinded Placebo Controlled Multicenter Trial to Evaluate the Efficacy Safety and Tolerability of Efgartigimod PH20 Subcutaneous Administered by Prefilled Syringe in Adult Patients with Primary Sjogrens Syndrome No dispute reported 06/30/2026 1237161332
Principal investigator 1 Janssen Research & Development, LLC $67.00 06/30/2025 Non-covered Recipient Entity
Hing Sheung Eugene Fung MD Pa
A Study of Guselkumab in Participants With Active Psoriatic Arthritis (APEX) No dispute reported 06/30/2026 1175291048
Principal investigator 1 Janssen Research & Development, LLC $230.00 06/30/2025 Non-covered Recipient Entity
Hing Sheung Eugene Fung MD Pa
A Study of Guselkumab in Participants With Active Psoriatic Arthritis (APEX) No dispute reported 06/30/2026 1175291133
Principal investigator 1 Janssen Research & Development, LLC $67.00 06/30/2025 Non-covered Recipient Entity
Hing Sheung Eugene Fung MD Pa
A Study of Guselkumab in Participants With Active Psoriatic Arthritis (APEX) No dispute reported 06/30/2026 1175291280
Principal investigator 1 Janssen Research & Development, LLC $2,412.00 06/30/2025 Non-covered Recipient Entity
Hing Sheung Eugene Fung MD Pa
A Study of Guselkumab in Participants With Active Psoriatic Arthritis (APEX) No dispute reported 06/30/2026 1175291286
Principal investigator 1 Janssen Research & Development, LLC $2,412.00 06/30/2025 Non-covered Recipient Entity
Hing Sheung Eugene Fung MD Pa
A Study of Guselkumab in Participants With Active Psoriatic Arthritis (APEX) No dispute reported 06/30/2026 1175291461
Principal investigator 1 Janssen Research & Development, LLC $67.00 06/30/2025 Non-covered Recipient Entity
Hing Sheung Eugene Fung MD Pa
A Study of Guselkumab in Participants With Active Psoriatic Arthritis (APEX) No dispute reported 06/30/2026 1175291468
Principal investigator 1 Janssen Research & Development, LLC $230.00 06/30/2025 Non-covered Recipient Entity
Hing Sheung Eugene Fung MD Pa
A Study of Guselkumab in Participants With Active Psoriatic Arthritis (APEX) No dispute reported 06/30/2026 1175291485
Principal investigator 1 Janssen Research & Development, LLC $271.00 06/30/2025 Non-covered Recipient Entity
Hing Sheung Eugene Fung MD Pa
A Study of Guselkumab in Participants With Active Psoriatic Arthritis (APEX) No dispute reported 06/30/2026 1175291526
Principal investigator 1 Janssen Research & Development, LLC $67.00 06/30/2025 Non-covered Recipient Entity
Hing Sheung Eugene Fung MD Pa
A Study of Guselkumab in Participants With Active Psoriatic Arthritis (APEX) No dispute reported 06/30/2026 1175291562
Principal investigator 1 ARGENX US, INC. $159.00 06/18/2025 Non-covered Recipient Entity
Velocity Clinical Research
Quincy Model A Phase 3 Randomized Double Blinded Placebo Controlled Multicenter Trial to Evaluate the Efficacy Safety and Tolerability of Efgartigimod PH20 Subcutaneous Administered by Prefilled Syringe in Adult Patients with Primary Sjogrens Syndrome No dispute reported 06/30/2026 1237161194
Principal investigator 1 ARGENX US, INC. $214.80 06/18/2025 Non-covered Recipient Entity
Velocity Clinical Research
Quincy Model A Phase 3 Randomized Double Blinded Placebo Controlled Multicenter Trial to Evaluate the Efficacy Safety and Tolerability of Efgartigimod PH20 Subcutaneous Administered by Prefilled Syringe in Adult Patients with Primary Sjogrens Syndrome No dispute reported 06/30/2026 1237161199
Principal investigator 1 ARGENX US, INC. $35.80 06/18/2025 Non-covered Recipient Entity
Velocity Clinical Research
Quincy Model A Phase 3 Randomized Double Blinded Placebo Controlled Multicenter Trial to Evaluate the Efficacy Safety and Tolerability of Efgartigimod PH20 Subcutaneous Administered by Prefilled Syringe in Adult Patients with Primary Sjogrens Syndrome No dispute reported 06/30/2026 1237161203
Principal investigator 1 ARGENX US, INC. $573.00 06/18/2025 Non-covered Recipient Entity
Velocity Clinical Research
Quincy Model A Phase 3 Randomized Double Blinded Placebo Controlled Multicenter Trial to Evaluate the Efficacy Safety and Tolerability of Efgartigimod PH20 Subcutaneous Administered by Prefilled Syringe in Adult Patients with Primary Sjogrens Syndrome No dispute reported 06/30/2026 1237161207
Principal investigator 1 ARGENX US, INC. $668.50 06/18/2025 Non-covered Recipient Entity
Velocity Clinical Research
Quincy Model A Phase 3 Randomized Double Blinded Placebo Controlled Multicenter Trial to Evaluate the Efficacy Safety and Tolerability of Efgartigimod PH20 Subcutaneous Administered by Prefilled Syringe in Adult Patients with Primary Sjogrens Syndrome No dispute reported 06/30/2026 1237161211
Principal investigator 1 ARGENX US, INC. $8.05 06/18/2025 Non-covered Recipient Entity
Velocity Clinical Research
Quincy Model A Phase 3 Randomized Double Blinded Placebo Controlled Multicenter Trial to Evaluate the Efficacy Safety and Tolerability of Efgartigimod PH20 Subcutaneous Administered by Prefilled Syringe in Adult Patients with Primary Sjogrens Syndrome No dispute reported 06/30/2026 1237161216
Principal investigator 1 ARGENX US, INC. $5.25 06/18/2025 Non-covered Recipient Entity
Velocity Clinical Research
Quincy Model A Phase 3 Randomized Double Blinded Placebo Controlled Multicenter Trial to Evaluate the Efficacy Safety and Tolerability of Efgartigimod PH20 Subcutaneous Administered by Prefilled Syringe in Adult Patients with Primary Sjogrens Syndrome No dispute reported 06/30/2026 1237161220
Principal investigator 1 ARGENX US, INC. $77.40 06/18/2025 Non-covered Recipient Entity
Velocity Clinical Research
Quincy Model A Phase 3 Randomized Double Blinded Placebo Controlled Multicenter Trial to Evaluate the Efficacy Safety and Tolerability of Efgartigimod PH20 Subcutaneous Administered by Prefilled Syringe in Adult Patients with Primary Sjogrens Syndrome No dispute reported 06/30/2026 1237161224
Principal investigator 1 ARGENX US, INC. $155.25 06/18/2025 Non-covered Recipient Entity
Velocity Clinical Research
Quincy Model A Phase 3 Randomized Double Blinded Placebo Controlled Multicenter Trial to Evaluate the Efficacy Safety and Tolerability of Efgartigimod PH20 Subcutaneous Administered by Prefilled Syringe in Adult Patients with Primary Sjogrens Syndrome No dispute reported 06/30/2026 1237161228
Principal investigator 1 ARGENX US, INC. $75.20 06/18/2025 Non-covered Recipient Entity
Velocity Clinical Research
Quincy Model A Phase 3 Randomized Double Blinded Placebo Controlled Multicenter Trial to Evaluate the Efficacy Safety and Tolerability of Efgartigimod PH20 Subcutaneous Administered by Prefilled Syringe in Adult Patients with Primary Sjogrens Syndrome No dispute reported 06/30/2026 1237161232
Principal investigator 1 ARGENX US, INC. $21.35 06/18/2025 Non-covered Recipient Entity
Velocity Clinical Research
Quincy Model A Phase 3 Randomized Double Blinded Placebo Controlled Multicenter Trial to Evaluate the Efficacy Safety and Tolerability of Efgartigimod PH20 Subcutaneous Administered by Prefilled Syringe in Adult Patients with Primary Sjogrens Syndrome No dispute reported 06/30/2026 1237161236
Principal investigator 1 ARGENX US, INC. $85.40 06/18/2025 Non-covered Recipient Entity
Velocity Clinical Research
Quincy Model A Phase 3 Randomized Double Blinded Placebo Controlled Multicenter Trial to Evaluate the Efficacy Safety and Tolerability of Efgartigimod PH20 Subcutaneous Administered by Prefilled Syringe in Adult Patients with Primary Sjogrens Syndrome No dispute reported 06/30/2026 1237161241
Principal investigator 1 Aurinia Pharma U.S., Inc. $3,000.00 06/18/2025 Non-covered Recipient Entity
Hing-Sheung Eugene Fund, MD PA dba Arthritis & Ost
LUPKYNIS Registry Study No dispute reported 06/30/2026 1243930836
Principal investigator 1 Janssen Research & Development, LLC $67.00 05/28/2025 Non-covered Recipient Entity
Hing Sheung Eugene Fung MD Pa
A Study of Guselkumab in Participants With Active Psoriatic Arthritis (APEX) No dispute reported 06/30/2026 1175290986
Principal investigator 1 Janssen Research & Development, LLC $1,256.00 05/28/2025 Non-covered Recipient Entity
Hing Sheung Eugene Fung MD Pa
A Study of Guselkumab in Participants With Active Psoriatic Arthritis (APEX) No dispute reported 06/30/2026 1175290998
Principal investigator 1 Janssen Research & Development, LLC $1,399.00 05/28/2025 Non-covered Recipient Entity
Hing Sheung Eugene Fung MD Pa
A Study of Guselkumab in Participants With Active Psoriatic Arthritis (APEX) No dispute reported 06/30/2026 1175291032
Principal investigator 1 Janssen Research & Development, LLC $271.00 05/28/2025 Non-covered Recipient Entity
Hing Sheung Eugene Fung MD Pa
A Study of Guselkumab in Participants With Active Psoriatic Arthritis (APEX) No dispute reported 06/30/2026 1175291070
Principal investigator 1 Janssen Research & Development, LLC $230.00 05/28/2025 Non-covered Recipient Entity
Hing Sheung Eugene Fung MD Pa
A Study of Guselkumab in Participants With Active Psoriatic Arthritis (APEX) No dispute reported 06/30/2026 1175291078
Principal investigator 1 Janssen Research & Development, LLC $67.00 05/28/2025 Non-covered Recipient Entity
Hing Sheung Eugene Fung MD Pa
A Study of Guselkumab in Participants With Active Psoriatic Arthritis (APEX) No dispute reported 06/30/2026 1175291086
Principal investigator 1 Janssen Research & Development, LLC $67.00 05/28/2025 Non-covered Recipient Entity
Hing Sheung Eugene Fung MD Pa
A Study of Guselkumab in Participants With Active Psoriatic Arthritis (APEX) No dispute reported 06/30/2026 1175291190
Principal investigator 1 Janssen Research & Development, LLC $67.00 05/28/2025 Non-covered Recipient Entity
Hing Sheung Eugene Fung MD Pa
A Study of Guselkumab in Participants With Active Psoriatic Arthritis (APEX) No dispute reported 06/30/2026 1175291205
Principal investigator 1 Janssen Research & Development, LLC $67.00 05/28/2025 Non-covered Recipient Entity
Hing Sheung Eugene Fung MD Pa
A Study of Guselkumab in Participants With Active Psoriatic Arthritis (APEX) No dispute reported 06/30/2026 1175291338
Principal investigator 1 Janssen Research & Development, LLC $1,399.00 05/28/2025 Non-covered Recipient Entity
Hing Sheung Eugene Fung MD Pa
A Study of Guselkumab in Participants With Active Psoriatic Arthritis (APEX) No dispute reported 06/30/2026 1175291352
Principal investigator 1 Janssen Research & Development, LLC $67.00 05/28/2025 Non-covered Recipient Entity
Hing Sheung Eugene Fung MD Pa
A Study of Guselkumab in Participants With Active Psoriatic Arthritis (APEX) No dispute reported 06/30/2026 1175291358
Principal investigator 1 Janssen Research & Development, LLC $230.00 05/28/2025 Non-covered Recipient Entity
Hing Sheung Eugene Fung MD Pa
A Study of Guselkumab in Participants With Active Psoriatic Arthritis (APEX) No dispute reported 06/30/2026 1175291583
Principal investigator 1 Janssen Research & Development, LLC $1,764.00 05/28/2025 Non-covered Recipient Entity
Hing Sheung Eugene Fung MD Pa
A Study of Guselkumab in Participants With Active Psoriatic Arthritis (APEX) No dispute reported 06/30/2026 1175291633
Principal investigator 1 ARGENX US, INC. $1,600.00 03/24/2025 Non-covered Recipient Entity
Hing-Sheung Eugene Fung MD PA
Quincy Model A Phase 3 Randomized Double Blinded Placebo Controlled Multicenter Trial to Evaluate the Efficacy Safety and Tolerability of Efgartigimod PH20 Subcutaneous Administered by Prefilled Syringe in Adult Patients with Primary Sjogrens Syndrome No dispute reported 06/30/2026 1237150703
Principal investigator 1 ARGENX US, INC. $8,000.00 03/24/2025 Non-covered Recipient Entity
Hing-Sheung Eugene Fung MD PA
Quincy Model A Phase 3 Randomized Double Blinded Placebo Controlled Multicenter Trial to Evaluate the Efficacy Safety and Tolerability of Efgartigimod PH20 Subcutaneous Administered by Prefilled Syringe in Adult Patients with Primary Sjogrens Syndrome No dispute reported 06/30/2026 1237150707
Principal investigator 1 ARGENX US, INC. $2,034.00 03/24/2025 Non-covered Recipient Entity
Hing-Sheung Eugene Fung MD PA
Quincy Model A Phase 3 Randomized Double Blinded Placebo Controlled Multicenter Trial to Evaluate the Efficacy Safety and Tolerability of Efgartigimod PH20 Subcutaneous Administered by Prefilled Syringe in Adult Patients with Primary Sjogrens Syndrome No dispute reported 06/30/2026 1237150711
Principal investigator 1 Janssen Research & Development, LLC $2,762.00 03/24/2025 Non-covered Recipient Entity
HING-SHEUNG EUGENE FUNG MD PA
Guselkumab in Active Psoriatic Arthritis Participants With Inadequate Response/Intolerance to One Prior Anti-TNF Alpha Agent No dispute reported 06/30/2026 1175401733
Principal investigator 1 Aurinia Pharma U.S., Inc. $5,022.00 03/12/2025 Non-covered Recipient Entity
Hing-Sheung Eugene Fund, MD PA dba Arthritis & Ost
LUPKYNIS Registry Study No dispute reported 06/30/2026 1243931054
Principal investigator 1 Janssen Research & Development, LLC $230.00 02/27/2025 Non-covered Recipient Entity
Hing Sheung Eugene Fung MD Pa
A Study of Guselkumab in Participants With Active Psoriatic Arthritis (APEX) No dispute reported 06/30/2026 1175290962
Principal investigator 1 Janssen Research & Development, LLC $1,225.00 02/27/2025 Non-covered Recipient Entity
Hing Sheung Eugene Fung MD Pa
A Study of Guselkumab in Participants With Active Psoriatic Arthritis (APEX) No dispute reported 06/30/2026 1175290970
Principal investigator 1 Janssen Research & Development, LLC $1,656.00 02/27/2025 Non-covered Recipient Entity
Hing Sheung Eugene Fung MD Pa
A Study of Guselkumab in Participants With Active Psoriatic Arthritis (APEX) No dispute reported 06/30/2026 1175290994
Principal investigator 1 Janssen Research & Development, LLC $271.00 02/27/2025 Non-covered Recipient Entity
Hing Sheung Eugene Fung MD Pa
A Study of Guselkumab in Participants With Active Psoriatic Arthritis (APEX) No dispute reported 06/30/2026 1175291063
Principal investigator 1 Janssen Research & Development, LLC $1,256.00 02/27/2025 Non-covered Recipient Entity
Hing Sheung Eugene Fung MD Pa
A Study of Guselkumab in Participants With Active Psoriatic Arthritis (APEX) No dispute reported 06/30/2026 1175291094
Principal investigator 1 Janssen Research & Development, LLC $67.00 02/27/2025 Non-covered Recipient Entity
Hing Sheung Eugene Fung MD Pa
A Study of Guselkumab in Participants With Active Psoriatic Arthritis (APEX) No dispute reported 06/30/2026 1175291212
Principal investigator 1 Janssen Research & Development, LLC $67.00 02/27/2025 Non-covered Recipient Entity
Hing Sheung Eugene Fung MD Pa
A Study of Guselkumab in Participants With Active Psoriatic Arthritis (APEX) No dispute reported 06/30/2026 1175291236
Principal investigator 1 Janssen Research & Development, LLC $67.00 02/27/2025 Non-covered Recipient Entity
Hing Sheung Eugene Fung MD Pa
A Study of Guselkumab in Participants With Active Psoriatic Arthritis (APEX) No dispute reported 06/30/2026 1175291293
Principal investigator 1 Janssen Research & Development, LLC $67.00 02/27/2025 Non-covered Recipient Entity
Hing Sheung Eugene Fung MD Pa
A Study of Guselkumab in Participants With Active Psoriatic Arthritis (APEX) No dispute reported 06/30/2026 1175291300
Principal investigator 1 Janssen Research & Development, LLC $2,653.00 02/27/2025 Non-covered Recipient Entity
Hing Sheung Eugene Fung MD Pa
A Study of Guselkumab in Participants With Active Psoriatic Arthritis (APEX) No dispute reported 06/30/2026 1175291313
Principal investigator 1 Janssen Research & Development, LLC $67.00 02/27/2025 Non-covered Recipient Entity
Hing Sheung Eugene Fung MD Pa
A Study of Guselkumab in Participants With Active Psoriatic Arthritis (APEX) No dispute reported 06/30/2026 1175291371
Principal investigator 1 Janssen Research & Development, LLC $2,761.00 02/27/2025 Non-covered Recipient Entity
Hing Sheung Eugene Fung MD Pa
A Study of Guselkumab in Participants With Active Psoriatic Arthritis (APEX) No dispute reported 06/30/2026 1175291426
Principal investigator 1 Janssen Research & Development, LLC $67.00 02/27/2025 Non-covered Recipient Entity
Hing Sheung Eugene Fung MD Pa
A Study of Guselkumab in Participants With Active Psoriatic Arthritis (APEX) No dispute reported 06/30/2026 1175291446
Principal investigator 1 Janssen Research & Development, LLC $1,656.00 02/27/2025 Non-covered Recipient Entity
Hing Sheung Eugene Fung MD Pa
A Study of Guselkumab in Participants With Active Psoriatic Arthritis (APEX) No dispute reported 06/30/2026 1175291515
Principal investigator 1 Janssen Research & Development, LLC $67.00 02/27/2025 Non-covered Recipient Entity
Hing Sheung Eugene Fung MD Pa
A Study of Guselkumab in Participants With Active Psoriatic Arthritis (APEX) No dispute reported 06/30/2026 1175291545
Principal investigator 1 Janssen Research & Development, LLC $67.00 02/27/2025 Non-covered Recipient Entity
Hing Sheung Eugene Fung MD Pa
A Study of Guselkumab in Participants With Active Psoriatic Arthritis (APEX) No dispute reported 06/30/2026 1175291553
Principal investigator 1 Janssen Research & Development, LLC $67.00 02/27/2025 Non-covered Recipient Entity
Hing Sheung Eugene Fung MD Pa
A Study of Guselkumab in Participants With Active Psoriatic Arthritis (APEX) No dispute reported 06/30/2026 1175291606
Principal investigator 1 Janssen Research & Development, LLC $1,256.00 02/27/2025 Non-covered Recipient Entity
Hing Sheung Eugene Fung MD Pa
A Study of Guselkumab in Participants With Active Psoriatic Arthritis (APEX) No dispute reported 06/30/2026 1175291613
Principal investigator 1 Janssen Research & Development, LLC $271.00 02/27/2025 Non-covered Recipient Entity
Hing Sheung Eugene Fung MD Pa
A Study of Guselkumab in Participants With Active Psoriatic Arthritis (APEX) No dispute reported 06/30/2026 1175291620
Recipient
Principal investigator 1
Kiniksa Pharmaceuticals International, plc $6,000.00 01/20/2025 Covered Recipient Physician KPL-404-C221 No dispute reported 06/30/2026 1254961150
Recipient
Principal investigator 1
Kiniksa Pharmaceuticals International, plc $2,000.00 01/20/2025 Covered Recipient Physician KPL-404-C221 No dispute reported 06/30/2026 1254961152
Recipient
Principal investigator 1
Kiniksa Pharmaceuticals International, plc $2,000.00 01/20/2025 Covered Recipient Physician KPL-404-C221 No dispute reported 06/30/2026 1254961154
Principal investigator 1 Janssen Research & Development, LLC $67.00 01/13/2025 Non-covered Recipient Entity
Hing Sheung Eugene Fung MD Pa
A Study of Guselkumab in Participants With Active Psoriatic Arthritis (APEX) No dispute reported 06/30/2026 1175291007
Principal investigator 1 Janssen Research & Development, LLC $67.00 01/13/2025 Non-covered Recipient Entity
Hing Sheung Eugene Fung MD Pa
A Study of Guselkumab in Participants With Active Psoriatic Arthritis (APEX) No dispute reported 06/30/2026 1175291024
Principal investigator 1 Janssen Research & Development, LLC $230.00 01/13/2025 Non-covered Recipient Entity
Hing Sheung Eugene Fung MD Pa
A Study of Guselkumab in Participants With Active Psoriatic Arthritis (APEX) No dispute reported 06/30/2026 1175291040
Principal investigator 1 Janssen Research & Development, LLC $67.00 01/13/2025 Non-covered Recipient Entity
Hing Sheung Eugene Fung MD Pa
A Study of Guselkumab in Participants With Active Psoriatic Arthritis (APEX) No dispute reported 06/30/2026 1175291056
Principal investigator 1 Janssen Research & Development, LLC $2,761.00 01/13/2025 Non-covered Recipient Entity
Hing Sheung Eugene Fung MD Pa
A Study of Guselkumab in Participants With Active Psoriatic Arthritis (APEX) No dispute reported 06/30/2026 1175291102
Principal investigator 1 Janssen Research & Development, LLC $67.00 01/13/2025 Non-covered Recipient Entity
Hing Sheung Eugene Fung MD Pa
A Study of Guselkumab in Participants With Active Psoriatic Arthritis (APEX) No dispute reported 06/30/2026 1175291109
Principal investigator 1 Janssen Research & Development, LLC $1,208.00 01/13/2025 Non-covered Recipient Entity
Hing Sheung Eugene Fung MD Pa
A Study of Guselkumab in Participants With Active Psoriatic Arthritis (APEX) No dispute reported 06/30/2026 1175291118
Principal investigator 1 Janssen Research & Development, LLC $67.00 01/13/2025 Non-covered Recipient Entity
Hing Sheung Eugene Fung MD Pa
A Study of Guselkumab in Participants With Active Psoriatic Arthritis (APEX) No dispute reported 06/30/2026 1175291143
Principal investigator 1 Janssen Research & Development, LLC $1,764.00 01/13/2025 Non-covered Recipient Entity
Hing Sheung Eugene Fung MD Pa
A Study of Guselkumab in Participants With Active Psoriatic Arthritis (APEX) No dispute reported 06/30/2026 1175291160
Principal investigator 1 Janssen Research & Development, LLC $67.00 01/13/2025 Non-covered Recipient Entity
Hing Sheung Eugene Fung MD Pa
A Study of Guselkumab in Participants With Active Psoriatic Arthritis (APEX) No dispute reported 06/30/2026 1175291181
Principal investigator 1 Janssen Research & Development, LLC $1,225.00 01/13/2025 Non-covered Recipient Entity
Hing Sheung Eugene Fung MD Pa
A Study of Guselkumab in Participants With Active Psoriatic Arthritis (APEX) No dispute reported 06/30/2026 1175291220
Principal investigator 1 Janssen Research & Development, LLC $67.00 01/13/2025 Non-covered Recipient Entity
Hing Sheung Eugene Fung MD Pa
A Study of Guselkumab in Participants With Active Psoriatic Arthritis (APEX) No dispute reported 06/30/2026 1175291250
Principal investigator 1 Janssen Research & Development, LLC $1,764.00 01/13/2025 Non-covered Recipient Entity
Hing Sheung Eugene Fung MD Pa
A Study of Guselkumab in Participants With Active Psoriatic Arthritis (APEX) No dispute reported 06/30/2026 1175291261
Principal investigator 1 Janssen Research & Development, LLC $67.00 01/13/2025 Non-covered Recipient Entity
Hing Sheung Eugene Fung MD Pa
A Study of Guselkumab in Participants With Active Psoriatic Arthritis (APEX) No dispute reported 06/30/2026 1175291271
Principal investigator 1 Janssen Research & Development, LLC $1,764.00 01/13/2025 Non-covered Recipient Entity
Hing Sheung Eugene Fung MD Pa
A Study of Guselkumab in Participants With Active Psoriatic Arthritis (APEX) No dispute reported 06/30/2026 1175291306
Principal investigator 1 Janssen Research & Development, LLC $271.00 01/13/2025 Non-covered Recipient Entity
Hing Sheung Eugene Fung MD Pa
A Study of Guselkumab in Participants With Active Psoriatic Arthritis (APEX) No dispute reported 06/30/2026 1175291331
Principal investigator 1 Janssen Research & Development, LLC $67.00 01/13/2025 Non-covered Recipient Entity
Hing Sheung Eugene Fung MD Pa
A Study of Guselkumab in Participants With Active Psoriatic Arthritis (APEX) No dispute reported 06/30/2026 1175291345
Principal investigator 1 Janssen Research & Development, LLC $271.00 01/13/2025 Non-covered Recipient Entity
Hing Sheung Eugene Fung MD Pa
A Study of Guselkumab in Participants With Active Psoriatic Arthritis (APEX) No dispute reported 06/30/2026 1175291395
Principal investigator 1 Janssen Research & Development, LLC $1,634.00 01/13/2025 Non-covered Recipient Entity
Hing Sheung Eugene Fung MD Pa
A Study of Guselkumab in Participants With Active Psoriatic Arthritis (APEX) No dispute reported 06/30/2026 1175291433
Principal investigator 1 Janssen Research & Development, LLC $1,634.00 01/13/2025 Non-covered Recipient Entity
Hing Sheung Eugene Fung MD Pa
A Study of Guselkumab in Participants With Active Psoriatic Arthritis (APEX) No dispute reported 06/30/2026 1175291439
Principal investigator 1 Janssen Research & Development, LLC $230.00 01/13/2025 Non-covered Recipient Entity
Hing Sheung Eugene Fung MD Pa
A Study of Guselkumab in Participants With Active Psoriatic Arthritis (APEX) No dispute reported 06/30/2026 1175291453
Principal investigator 1 Janssen Research & Development, LLC $67.00 01/13/2025 Non-covered Recipient Entity
Hing Sheung Eugene Fung MD Pa
A Study of Guselkumab in Participants With Active Psoriatic Arthritis (APEX) No dispute reported 06/30/2026 1175291477
Principal investigator 1 Janssen Research & Development, LLC $2,653.00 01/13/2025 Non-covered Recipient Entity
Hing Sheung Eugene Fung MD Pa
A Study of Guselkumab in Participants With Active Psoriatic Arthritis (APEX) No dispute reported 06/30/2026 1175291501
Principal investigator 1 Janssen Research & Development, LLC $2,032.00 01/13/2025 Non-covered Recipient Entity
Hing Sheung Eugene Fung MD Pa
A Study of Guselkumab in Participants With Active Psoriatic Arthritis (APEX) No dispute reported 06/30/2026 1175291506
Principal investigator 1 Janssen Research & Development, LLC $67.00 01/13/2025 Non-covered Recipient Entity
Hing Sheung Eugene Fung MD Pa
A Study of Guselkumab in Participants With Active Psoriatic Arthritis (APEX) No dispute reported 06/30/2026 1175291577
Principal investigator 1 Janssen Research & Development, LLC $67.00 01/13/2025 Non-covered Recipient Entity
Hing Sheung Eugene Fung MD Pa
A Study of Guselkumab in Participants With Active Psoriatic Arthritis (APEX) No dispute reported 06/30/2026 1175291592
Principal investigator 1 Janssen Research & Development, LLC $230.00 01/13/2025 Non-covered Recipient Entity
Hing Sheung Eugene Fung MD Pa
A Study of Guselkumab in Participants With Active Psoriatic Arthritis (APEX) No dispute reported 06/30/2026 1175291599
Principal investigator 1 Janssen Research & Development, LLC $67.00 01/13/2025 Non-covered Recipient Entity
Hing Sheung Eugene Fung MD Pa
A Study of Guselkumab in Participants With Active Psoriatic Arthritis (APEX) No dispute reported 06/30/2026 1175291648